Institut Curie

Institut Curie is a French foundation of public interest, which combines one of the largest European oncology research center and two state-of-the-art hospitals. Founded in 1909 on a model devised by Marie Curie and still at the cutting edge: "from fundamental research to innovative treatments", the Institut Curie has 3,000 researchers, physicians, clinicians, technicians and administrative staff.

Huazhong University of Science & Technology

Huazhong University of Science & Technology (HUST) in Wuhan (China) has grown into a dynamic university enjoying social support and good reputation and shouldering a historical mission. It distinguishes itself among domestic universities by virtue of its rapid growth, pragmatism and efficient use of resources. It commits itself to the task of dissemination of existing knowledge and creation of new knowledge. It strives to cultivate capable and innovative young minds and to serve both individual and global needs. HUST is also a research-based university which maintains close ties with business and industry

Sino French School of Oncology

Supported by the Ambassade de France en Chine
Background: Cancer is a major health problem in the world, however, education efforts against cancer is still not uniform worldwide. It has been recognized that a complete and proper teaching portfolio should include learning on cancer control (epidemiology, prevention and screening), clinical skills, patients communications skills and palliative care.
Mission: Increase the connections between France and China to strength the progress against Cancer – Particularly in the Hubei province.
Our approach: Introduction to young professionals all the major aspects of oncology to progress against cancer. The course integrates the complexity from the basic principles of oncogenesis to diagnosis and therapeutic management of the most aggressive tumors.

PopsiCube

Our expertise stems from many years of experience spent inside the largest CRO or pharmaceutical companies. We always considered IT as a valuable tool and as a way to improve and industrialize processes. It is our in-depth knowledge of pharmaceutical R&D which allows us to transform these tools to support a real advance in your clinical projects.
The origin of Popsi Cube is a convergence between a solid clinical process and effective IT tools.
A CRO with integrated tools to address the entire clinical research functional scope.
A successful project management requires top quality human resources but also a set of tools supporting a simple, pertinent and effective decision process. Popsi Cube did not find any off-the-shelf system that would meet these objectives. We therefore have developed a set of tools specifically adapted to our services.

Université d'Evry

The Université d’Evry-Val-d’Essonne is located 30 km south of Paris. It is a multidisciplinary university, associated to the Université Paris-Saclay, with whom it shares Research Masters and PhD schools. The UEVE offers to its 10 000 students 160 diplomas distributed over 5 research and formation poles. The UEVE includes a School of Engineering (ENSIIE) and a Vocational training center. UEVE is strongly linked to the Evry Genopole Biocluster. UEVE and Genopole have in common 18 Research Laboratories.

Life Sciences Leadership School

Based in Paris, LS LEAD purpose is to achieve knowledge transfer to talented professionals without disrupting their professional lives: Achieve the transfer of solid experience-based skills by recognized expert professionals in innovative Life Sciences Businesses To talented professionals who intend to become leaders ready to successfully create and manage innovative health care companies in a competitive international environment.

Dr Jean-Philippe Pin

Jean-Philippe Pin get trained at the Ecole Normale Supérieure in Paris, and got his PhD in Molecular Biology in 1987 at the University of Montpellier (France). He participated in the discovery of the metabotropic glutamate receptors. As a post-doctoral fellow at the Salk Institute, he cloned ... and characterized new mGlu receptor variants. In 1992, he joined Joël Bockaert's laboratory in Montpellier and lead a team focused on the structure function relationship of mGluRs. Since 2003, he is head of the Molecular Pharmacology Department within the Institute of Functional Genomics (Montpellier, France), and became director of this Institute in January 2011. His research is focused on the molecular and cellular dynamics of GPCRs, mostly mGlu and GABAB receptors. Over the recent years he developed innovative approaches to study cell surface receptors, including biosensors and photoswitchable ligands. His studies led to new concepts in the GPCR field, such as: the activation of cell surface receptors by intracellular proteins; the regulation of GPCRs by both negative and positive allosteric modulators, the asymmetric functioning of GPCR dimers.

Dr GREGOIRE PREVOST

Grégoire is now CEO of CIPREVO based in France which is a unique expertise provider supporting research and development projects in Oncology. Grégoire brings 29 years of experience in Oncology research and development. He obtained his PhD in Molecular and Cellular Biology in 1989 at the Institut Pasteur of Paris/ University of Tours (France), and continued his scientific career as a post-doctorate at IOCMH (Bobigny, France) and BIOMEASURE (Milford, MA, USA). In 1995, he was appointed as Oncology research leader at Beaufour-IPSEN (Les Ulis, France) and held progressive positions at IPSEN, among which Oncology Translational Research Director, Oncology Scientific Affairs Director and member of the Oncology Portfolio Management Team. In March 2011, Grégoire joined InteRNA Technologies (Utrecht, The Netherlands) as Chief Development Officer and in 2013 created his own company CIPREVO to support R&D Oncology projects. He has participated to the transfer of 3 drug candidates to the clinic and has been a significant contributor to Oncology field with more than 100 scientific publications and patent families. In addition in 2012, he co-founded the Sino-french School of Oncology in Wuhan with Professor Jianfeng Liu from HUST, Wuhan.

Zhang Luoying

Our research interest is in understanding the regulatory mechanism and function of sleep and circadian rhythm. We are exploring how circadian clock regulates sleep and other biological processes using a system’s approach. We are particularly interested in understanding how circadian rhythm and sleep affects mood, as well as the connections between circadian/sleep disruptions and psychiatric disorders.

Dr. Bertrand Duvillié

Following his graduation in genetics at University Paris 7 (M Sc.), Bertrand Duvillié studied brain development for one year in the laboratory of Dr Charnay at Ecole Normale Supérieure (Paris, France). Next, he oriented his educational cursus on pancreas development. Indeed, his objective was to understand the mechanisms that control the pancreatic progenitor cell differentiation into mature beta cells and to contribute on a long term to define new protocols for a cell-therapy of diabetes. Thus, he joined the team of Dr Jami for his PhD (Cochin Institute, Paris) where he generated and analyzed insulin 1 and insulin 2 mutant mice in order to decipher the roles of embryonic insulin in pancreas development. To deepen his knowledge in the effect of growth factors, he next spent 3 years at London (Ontario, Canada), in the laboratory of Prof. David J. Hill. In particular, he analyzed the effects of Insulin-like Growth Factors on the proliferation and survival of pancreatic islet cells. In 2000, he was recruited at INSERM as a researcher in the laboratory of Prof. Czernichow. From 2000 to 2006, he worked with Dr R Scharfmann, and he studied the role of Fibroblast Growth Factors in pancreas development, both in rodents and humans. He also investigated the effects of the mesenchyme on beta-cell development through the activation of the Notch pathway. Since 2006 to 2016, he continued his research as a junior group leader, in the same unit (directed by Dr Scharfmann at Faculty Necker 2006-2011, and next at Cochin Institute 2012-2016). His investigations were focused on the role of environmental factors in pancreas development. In particular, he showed that not only oxygen tension, but also reactive oxygen species (ROS) control the expression of the pro-endocrine transcription factor Ngn3 in the pancreas. Since 2016, Bertrand Duvillié joined the laboratory of Celio Pouponnot and Alain Eychene at the Curie Institute. His global objective is to better understand the signals that control endocrine tumorigenesis. In particular he aims to analyze the role of intra-cellular signals using engineered mice models that mimic human pathologies.

Nathalie MAZURE

Nathalie Mazure is a senior scientist and research director at the CNRS at the Institute for Research on Cancer and Aging, Nice (IRCAN) in France. Since 1994, she has contributed to the field of hypoxia by understanding the mechanisms of gene regulation under hypoxic conditions. As hypoxia is more a stimulation for the survival of tumor cells, she focused on the resistance to cell death of hypoxic cancer cells. She found that different mechanisms, such as autophagy or microfusion between mitochondria and endolysosomes, confer such a resistance. Recently, her main interest is on hypoxic mitochondria with the objective to identify new targets involved in both metabolism and survival.

Marie-Anne Debily

Marie-Anne Debily got her PhD in Molecular Biology in 2003 at the University of Paris 6 and a training in bioinformatic in Pasteur Institute. She then joined the Japan Biological Information Research Center (Tokyo Japan) for a post-doctoral fellowship as part of the international H-invitational consortium to initiate a comprehensive functional link between the genome sequence scaffold and human diseases. Since 2005, she is assistant professor in Evry University and contributed in the functional genomics field. First, she focused on the regulation networks of epidermis differentiation and conducted genome-wide screening of interfering RNA inducing synthetic lethality of cancer cells harboring oncogenic mutations in CEA (Commissariat à l’Energie Atomique, Evry France). Since 2013, she developed in Gustave Roussy Institute (Villejuif France) an integrative research program dedicated to a universally fatal pediatric brain tumor, Diffuse Intrinsic Pontine Glioma, to both understand molecularly their unique biology, define the pathogenic mechanisms and identify new promising target in this disease.

Xue Yu

Dr. Xue has published over 60 SCI papers, with a citation of >2,000 times. He is an academic Editor of PLoS ONE & Scientific Reports, and an associate Editor of BMC Genomics. He is also an active blogger for ScienceNet (http://blog.sciencenet.cn/u/DaCaiNiao). He is quite active on pushing the communication and collaboration of young bioinformatists in China. Dr. Xue hope to resolve ALL computational problems for PTMs, but perhaps this aim might not be realized until his retirement. He is Editor-in-Chief of « Frontiers in Cellular Endocrinology », the director of the GDR-3545 "The French GPCR Network – from physiology to drugs" of the CNRS and the Chair of NC-IUPHAR « Melatonin receptor » sub-committee.

Ralf Jockers

Ralf Jockers studied in Cologne and received a PhD in biotechnology and biochemistry from the University of Braunschweig, Germany. For postdoctoral training he joined the laboratory of Dr. AD Strosberg at Cochin Institute, Paris, where he worked on the regulation of ß-adrenergic receptors. Since 1998 he holds a permanent position at INSERM, France. He published more than 150 scientific papers and delivered more than 100 invited conferences. His research centers on the allosteric regulation and function of G protein-coupled receptors in relation to receptor variants and receptor-associated complexes. For the last ten years his group has been actively working on MT1 and MT2 melatonin receptors. He recently showed the involvement of multiple rare mutations of the MT2 receptors in type 2 diabetes development and the importance of MT1/MT2 heteromers in retinal physiology. He is Editor-in-Chief of « Frontiers in Cellular Endocrinology », the director of the GDR-3545 "The French GPCR Network – from physiology to drugs" of the CNRS and the Chair of NC-IUPHAR « Melatonin receptor » sub-committee.

Patrick Curmi

Président de l’Université d’Evry, France

Li Su

College of Life Science and Technology, Huazhong University of Science and technology,Wuhan, China. Key Laboratory of Molecular Biophysics of the Ministry of Education College of Life Science and Technology Huazhong University of Science and Technology (HUST) 1037, Luoyu Road, Hubei, Wuhan, 430074,

Philippe Rondard

Philippe Rondard received his Ph.D from the University of Paris 7 in 1998. During the period of 1993-1998, he was trained at Pasteur Institute (Paris, France) in protein biochemistry. In 1998, he joined Henry Bourne's laboratory at University of California San Francisco, as a postdoctoral fellow. He studied the molecular mechanism of G-protein activation. Since 2001, he is working within Jean-Philippe Pin's laboratory. Since 2008, he’s leading a research group within this laboratory. Dr. Rondard's main research interest has been the molecular mechanism of activation of class C G protein-coupled receptors (GPCRs) with focus on the metabotropic glutamate and GABA-B receptors. He has developed several biochemical and biophysical approaches based on the technique of time-resolved FRET. Recently, he developed single domain antibodies from llamas (nanobodies) to detect and modulate GPCR signaling.

Helen Boyle

The Centre Léon Bérard is the regional cancer center. Dr Helen Boyle is involved in the treatment of patients with urological cancers (prostate, bladder, testis and kidney mainly).

Fabrice Beauchêne

Fabrice is a serial entrepreneur, with more than 20 years experience in life science busineses,IT projects management and fund raising.

Sylvie Kahn

Sylvie has more than 30 years in Clinical Development of drugs and medical devices in top 10 Pharma and CROs. She is a certified trainer in Clinical Research.

Dr. Pierre Saintigny

Appointements -01/2014-current: Médecin Spécialiste de CLCC, Centre Léon Bérard, Lyon, France -06/2013-12/2013: Praticien de CLCC, Centre Léon Bérard, Lyon, France -2011-2013: Assistant Professor (2 yrs.), Dpt. of Thoracic/Head&Neck Medical Oncology (THNMO), The University of Texas M.D. Anderson Cancer Center (UTMDACC), Texas -2009-2010: Research Scientist (1 yr.), Dpt. of THNMO, UTMDACC, Houston, Texas -2003-2007: Assistant des hôpitaux de Paris-Chef de Clinique à la faculté (4 yrs.), Dpt of Medical Oncology, Avicenne Hospital, University of Paris 13 Medical School Current affiliations -Cancer Research Center of Lyon, Department of Cancer Cell Plasticity, Team « EMT and Cancer Cell Plasticity » (A. Puisieux), UMR INSERM 1052 / CNRS 5286 Mixte CLB -Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France -Department of Medicine, Centre Léon Bérard, Lyon, France Management and administrative experience - Coordinator of the Tumor Characterization Unit that includes the following platforms: Pathology Research, the platform of Bioinformatics-Gilles Thomas, the Biobank, and the platform of Genomics, in the Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France - Director of the Laboratory of Translational Research and Innovation, in the Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France - Member of the Medical Technical Committee of the Biobank (Comité Médico-Technique du Centre de Ressources Biologiques) - Member of the CLB-CRCL Valorization Committee (Comité de Valorisation) - Member of the CRCL Executive Operational Committee (Comité de Direction Opérationnelle) 2 - Member of the CLARA Regional Network Scientific Committee (Comité de Pilotage Scientifique du Cancéropôle Lyon Auvergne Rhône-Alpes) - Member of the Synergie Lyon Cancer Foundation Scientific Committee (Comité de Pilotage Scientifique, Fondation Synergie Lyon Cancer) Education In France: - French Baccalaureate (1991, with honors, Lycée du Caire, R.A.E.) - 1991-1997: Medical School, Paris Descartes Medical School, University of Paris 5 (MD degree) - 1997-2003: Clinical Fellowship, Internal Medicine & Medical Oncology, University of Paris [Thèse de Médecine (2003) ; Diplôme d’étude Spécialisée en Médecine Interne, Paris 5 (2003) ; Diplôme d’étude Spécialisée Complémentaire en Cancérologie, Paris 5 (2004) ; qualification ordinale en Oncologie Médicale, 2006] - D.U. de Carcinologie Clinique, Paris 11 (1999) - D.I.U. d’Hématologie et Cancérologie du Sujet Âgé, Paris 6 (2005) - 2001-2002: Master in Oncology (Cellular Biology and Genetics), University of Paris 11-ENS Cachan - 2005-2007: PhD degree, University of Paris 13 University - D.U. de Pédagogie Médicale, Université Lyon Sud (2016) In the USA: -2007-2009: Postdoctoral Fellowship (2 yrs.), Dpt of THNMO, UTMDACC, Houston, Texas -2009: ECFMG (Educational Commission for Foreign Medical Graduates) Step 1, 2CK, 2CS -2009: USMLE (United States Medical Licensing Examination) Step 3 -2010-2011: Clinical Fellowship (1 yr.), Dpt of THNMO, UTMDACC, Houston, Texas Honors -2001: Award from the Fonds d’Etude du Corps Medical des Hôpitaux de Paris: « Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for the diagnosis of lymph node micrometastasis in nonsmall-cell lung carcinoma » -2001 Award from the Fondation Martine Midy: « Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for the diagnosis of lymph node micrometastasis in non-small-cell lung carcinoma » -2003 University of Paris Medical School Silver Medal-Faculté de Médecine Paris Descartes, Université Paris 5, Paris, France -2005 Astra-Zeneca Award: « Evaluation of biological factors associated with lymph node metastasis in patients resected for a non-small-cell lung cancer » -2010 Nature Publishing Group Award for Individualized Tailored Treatment at the Worldwide Innovative Networking (WIN) in personalized cancer medicine symposium: « MYC down-regulation and chemoresistance: evidence from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program » Research Evaluation - Member of the ITMO Cancer group of experts on the stakes and future directions on cancer immunotherapy - Referee for the “Agence National pour le Recherche” 3 -Referee for international journals (Clinical Cancer Res, Cancer Res, Lung Cancer, Cancer Prev Res, BMC Cancer, Histology & Histopathology, Journal of Experimental & Clinical Cancer Research, Journal of Surgical Oncology, Journal of Thoracic Oncology, Lung Cancer, British Journal of Cancer, Cancer Biology & Therapy, International Journal of Oral & Maxillofacial Surgery, Medical Oncology…) Research Grants -2016-2019: PRT-K16-023: Association between Tertiary Lymphoid structures, tumor mutational landscape and anti-tumor immunity: impact for immune check point-based therapy in lung and breast cancers; Role: co-investigator; 670k€ -2016-2019: PLBIO16-313: «Characterization of a putative novel epigenetic regulator of gene expression in breast cancer » ; Role : Co-Investigator ; 665k€ -2016-2019: TABAC16-025: « Intensive and sustained smoking cessation program for patients with head and neck cancer: a pragmatic randomized intervention study »; Role: Coordinator; 523k€ -Fondation de France AAP 2015 Recherche fondamentale et clinique sur le cancer : « Role of immune checkpoints in epithelial-mesenchymal transition mediated immune evasion in lung adenocarcinomas » (postdoctoral funding for Sandra Ortiz-Cuaran) ; 170k€ -2015-2018: PLBIO15-266: « Role of immune checkpoints in epithelial-mesenchymal transition mediated immune evasion in breast and lung cancers »; Role: Coordinator; 629k€ -ERA-Net TRANSCAN-2-Joint Translational Call for Proposals (JTC 2014): « Patient-derived models for intratumour functional heterogeneity and its implications for personalized medicine (BeFIT) »; Role: co-Investigator (PI: Patrick Mehlen); 300k€ -2014-2016: Programme Structurant, Regional Cancer Network (CLARA); (International) Head and Neck Prevention Act; Role: Consortium Coordinator; 375k€ -2012-2013: Head and Neck SPORE Career Development Award (CDA) (5 P50 CA097007 09): Comprehensive characterization and sequence of molecular changes leading to the transformation of oral premalignant lesions; Role: PI; $90k -2011-2012: Head and Neck SPORE CDA (5 P50 CA097007 09): Epigenetic Modifications in Oral Preneoplasia and Their Association with the Development of Oral Cancer; Role: PI; $100k -2007-2010: National Hospital Clinical Research Program (PHRC AOM05176); 250k€; Multicenter and prospective evaluation of the prognostic value of lymph node micrometastasis detected by real time PCR in patients resected for a NSCLC; PI: F Le Pimpec-Barthes; Role: Co-PI -2004-2006: Regional Hospital Clinical Research Program (PHRC AOR03015); 200k€; MDR1 gene polymorphisms and response to anthracyclines and taxanes in breast cancer; PI: A Fajac; Role: CoInvestigator Teaching Outside of Current Institution - 2004: High-dose chemotherapy and dose-density in solid tumors (XIXth Course on Antitumor Chemotherapy and Medical Treatment of Cancer, Institut Gustave Roussy) - 2003 – 2007: Medical Oncology, University Paris 13 Medical School - 2005 – 2007: Thoracic Oncology (Master’s Diploma, University of Paris) - 2003 – 2007: Oncology, Hôpital Avicenne School of Nurse

Yong Liu

Dr. Yong Liu received his Bachelor and Master degrees in Biochemistry from Peking University in 1986 and 1989, respectively. He obtained his Ph.D. degree in 1995 in Microbiology and Molecular Genetics from Rutgers-The State University of New Jersey and UMDNJ-RWJ Medical School. After his post-doctoral training at University of California, Santa Barbara from 1995 to 2000, Dr. Liu worked as a Senior Scientist at the Immunology Section of AlleCure/Mankind Corp., a California-based biotechnology company. In 2003, Dr. Liu joined the Institute for Nutritional Sciences as a Principal Investigator at SIBS, Chinese Academy of Sciences in Shanghai. In 2015, he moved to Wuhan and joined the College of Life Sciences at Wuhan University as a Professor. Dr. Liu has received a number of awards, including the Distinguished Young Scientist Award from National Natural Science Foundation of China in 2009. He has also served as the Principal Investigator for a 973 NAFLD research program from the Ministry of Science and Technology of China. Dr. Liu’s research has focused upon elucidating the molecular and cellular mechanisms that link overnutrition, cellular stress pathways and metabolic disorders. Currently, Dr. Liu’s group is interested in exploring the physiological actions of the IRE1 signaling arm of the cellular unfolded protein response (UPR) in nutrient-sensing and metabolic homeostasis. Employing animal models, his group is investigating the mechanisms by which the IRE1 pathway disturbs the homeostatic regulation of metabolism in the settings of overnutrition-induced metabolic ER stress. These studies will provide new insights into the key role of ER stress pathways in the pathogenic progression of obesity, type 2 diabetes, NAFLD and other metabolic diseases.

Jianmiao Liu

Academic Areas：Angiogenesis, vascular remodeling Research Interests： Mechanism of endoplasmic reticulum stress-induced endothelial dysfunction. Study of mechanosensors on the endothelium by microfluidic technology Academic Degrees： PhD in Biologic and Medical engineering, 2002, University of Paris 13, France BA Biochemistry, 1996, WuHan University, Wuhan, Hubei, China Professional Experience： Professor (2010-present); College of Life Science & Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China Research Engineer (2008-2013); Institute of Natural Product Chemistry, Centre national de la recherche scientifique UPR 2301, Gif-sur-Yvette, France

Prof. Bifeng Liu

His research focuses on systems biology-oriented analytical science in the areas of microfluidics (or lab-on-a-chip) for bioanalysis, mass spectrometry coupled micro-separations for functional proteomics & molecular imaging. He is the author and co-author of over 100 original research papers and invited reviews published in international journals.

Dr. Shangbang GAO

Education （in time-reversed order） 2003 -2008 Ph.D. in Biophysics (08/2006 - 06/2008) Institute of Biophysics, Chinese Academy of Sciences (CAS), Beijing, China. (09/2003 - 08/2006) Huazhong University of Sci. and Techn., Wuhan, China. 1999 - 2003 B.S. in Biomedical Engineering Huazhong University of Sci. and Techn., Wuhan, China. Research Experience （in time-reversed order） 2015-now Professor, College of Life Science and Technology, HuaZhong University of Science and Technology, Wuhan, China. Molecular and neuronal circuit mechanisms of behaviors 2008-2015 Postdoctoral Fellow, University of Toronto, Canada. Deciphering the molecular and circuit mechanisms of locomotion in C. elegans

PENG YU

Foreign Corresponding Member of the National Academy of Pharmacy (France) Director of Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry Director of China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry Dec. 2009-Now Professor /Eminent Scholar/Thousand Talents Plan of Tianjin Associate Dean of College of Biotechnology, Tianjin University of Science & Technology Feb. 1999 – Feb. 2009 Sr. Research Scientist/Group Leader deCODE Chemistry, Woodridge, IL, USA Aug. 1993 – Dec. 1998 Graduate Assistant, Department of Chemistry, University of Wisconsin-Milwaukee (Ph. D.) Aug. 1990 – Aug. 1993 Lecturer Department of Chemistry, Shanxi University, Taiyuan, P. R. C. Aug. 1987 – Aug. 1990 Research Assistant Institute of Molecular Science, Shanxi University, Taiyuan, PRC (M. S.) Aug. 1979– July 1983 Department of Chemistry, Shanxi University, Taiyuan, P. R. C (B.S.)

PENG YU

Education （in time-reversed order） 2003 Habilitation to supervise research (HDR); University of Evry 1996 PhD, University of PARIS XI Research Experience （in time-reversed order） Since Jan 2017 – DR1 INSERM, dir. INSERM U1242, Univ. Rennes 1, CLCC Eugène Marquis, Rennes. March 2015 – Dec 2016 – DR2 INSERM, ER440 Univ. Rennes 1, CLCC Eugène Marquis, Rennes. Jan 2010- present – DR2 INSERM U1053, Bordeaux Jan 2007- Jan 2012 – Head Team Avenir, “Endoplasmic Reticulum stress & cancer” Dec 2006- Dec 2010 - Researcher (CR1) INSERM U1053, Bordeaux Sept 2001-Dec 2006 – Assistant Professor, McGill University, Montreal, Qc, Canada Jan 1997- Aug 2001 - Post-Doctoral fellow, McGill University, Montreal, Qc, Canada Sept 1993 – Dec 1996 – PhD Thesis, Univ. PARIS XI, France Summary academic achievements: Eric Chevet is Research Director at the French National Institute for Health and Medical Research (Inserm). After a Ph.D. in Molecular Cell Biology from the University of Paris in 1996 and a post-doctoral fellowship at McGill University (Canada), he established his own laboratory at McGill University in 2001 before going back to France in 2006. For the past 15 years he has been investigating the role of endoplasmic reticulum stress signaling and proteostasis control in cancer development. Early 2015, he moved to Rennes in the West part of France to head a Cancer Research Laboratory within the Comprehensive Cancer Centre Eugène Marquis”. The main objective of this research centre will be to characterize select stress signaling pathways (including ER stress, death receptors, DNA damage) in various cancers and develop novel relevant therapeutics to impede cancer development. Eric Chevet has authored more than 140 publications and few patents.

Christian Cavé

Professor Christian Cavé received his Pharm D in 1980 and this Ph. D. in 1986 from Paris Sud University. From 1986 to 1990, he was project leader in Medicinal Chemistry (Meram Laboratories, France). Then he worked , as assistant professor (1990-1997) at the Faculty of Pharmacy of University Paris in the Group of Organic Chemistry ( Professor Jean D'Angelo) and as full professor of Organic Chemistry at University of Burgandy (Dijon) . Then he moved to Faculty of Pharmacy of University Paris Sud in 2002 and he is a full Professor from 2002.. He was the Head of the research team "Organic chemistry and pharmacochemistry " in the UMR CNRS BioCIS (2002/2008) and then joined the group of Antiparasite Chemotherapy , UMR-CNRS BioCIS 8076, at the Faculty of de Pharmacy, University Paris-Saclay. His research interests comprise synthetic organic; Asymmetric synthesis: Asymmetric Michael Reaction; Medicinal Chemistry in the field of alzheimer’ disease, HIV, cancer, leishmaniasis, and malaria; Pharmaceutical Chemistry: Biotransformation, QSAR In Organic Chemistry, we develop synthetic tools that we then use in medicinal chemistry.For example, we have developed the Asymmetric Michael reaction onto acyclic ketones or acyclic or acyclic  ketoesters via chiral imines or enaminoesters derivatives Thus, new chiral ketophosphonates and new chiral -hydroxy esters have been made in order to have access to new analogues of metabotropic glutamate receptors that are highly involved in Alzheimers Disease. Currently we are working on click chemistry in order to synthesize new compounds usable in medicinal chemistry. He is the author or co-author of over 90 scientific papers. He is responsible for the Master degree in Pharmaceutical sciences- https://www.universite-paris-saclay.fr/fr/formation/master/sciences-du-medicament#mention He is member of executive committee of school " Biology, Medecine and pharmacy", University Paris Saclay He is Member of editorial boards of various chemical and pharmaceutical reviews; He is member of Executive Committee of European Association of Faculties of Pharmacy (EAFP) https://www.eafponline.eu, member of Executive Committee of Société de Chimie Thérapeutique (French Society of Medicinal Chemistry) https://www.sct-asso.fr/, member of ACS (American Chemical Society) and SFC (French Chemical Society). he has received many honors: Graduate of the Faculty of Pharmacy Paris-Sud; Auguste Béhal Prize for studies and researches, Roussel Prize for Researches in the field of Medicinal Chemistry, Chevalier dans l’ordre des palmes académiques Member of UiTM Academic Advisory Panel for Faculty of Pharmacy, Kuala Lumpur, Malaisie, visiting Professor at Guiyang College of Traditional Chinese Medicine, guest professor of Guizhou Institut of Technology.

Dr Olivier Lavergne

Dr Olivier Lavergne is the founder and CEO of Chem4LS, a consultancy in medicinal chemistry and preclinical research. After studying industrial chemistry in Lyon 5France) he moved to Wayne State University in Detroit (Michigan) where he obtained his PhD with Pr Carl Johnson. Starting his carreer with the Beaufour-Ipsen group in Barcelona (Spain) and pursuing at the Henri Beaufour Institute in Paris (France), he has contributed to numerous research projects with small molecules, peptides and small proteins. Dr Lavergne has extensive experience in drug design in disease areas spanning oncology, endocrinology and CNS, employing a wide array of approaches including immune check-point modulation, DNA intercalation, cross-linking and damaging agents, cell cycle control check-points, steroid-cascade enzymes inhibition, phosphatase and kinase inhibitors, GPCR ligands and allosteric modulation. Dr Lavergne current research interests include novel modalities of drug discovery including Deap Learning methods. Contact email: ol.chem4ls@gmail.com

Professor Jianfeng LIU

Vice director,Key laboratory of molecular biophysics of ministry of education - HUST Wuhan, China

Wang Chenhui

Research Interests: My lab is to try to understand the molecular mechanism of many autoimmune diseases, such as inflammatory bowel diseases, multiple sclerosis, type I diabetes, rheumatoid arthritis et al, and try to find new signaling or targets involved in the diseases.

Hervé Galons

The research is organized in two different labs: The University in Paris and the biotech company: ManRos Therapeutics founded in 2007 with Dr Laurent Meijer. In both labs most of the ongoing research programs are related to kinase inhibition or compounds to treat diseases related to protein misfolding. These two labs have their own complete equipment for chemistry including a 400 MHz NMR apparatus. A collaboration was recently started with the Med Chem lab directed by Prof. Yu Peng at Tianjin University for Science and Technology.

Bo Hu

Bo Hu got his PhD in Inorganic Chemistry in 2008 at the University of Science and Technology of China (China), and continued his scientific career as a post-doctorate at the University of Science and Technology of China (Hefei, China), Northwestern University (Evanston, IL, USA), University of Cincinnati (Cincinnati, OH, USA), and Washington University in St. Louis (St. Louis, MO, USA). In 2015, he joined School of Life Science and Technology in the Xidian University. He has authored and co-authored more than 30 refereed journal publications published in Adv. Mater., Adv. Funct. Mater., ACS Nano etc. (citations 2292, H index= 18), 2 invited book chapters, and 6 patents. His research interests are focused on the molecular imaging and sensing, which has the characterization of multidisciplinary cross connection. Based on the clinic problems, he uses multi-technology, including nanotechnology, 3D printing, microfluidics, molecular biology, artificial intelligence and electronic engineering for the development of diagnosis system of diseases.

Hélène Castel

Hélène Castel started to develop different variants of the electrophysiological technique at the University of Rouen in the Neuroendocrinology laboratory of Dr Vaudry (U413 Inserm) to give a comprehensive view of modulation of the GABAA receptor-channel function by interacting proteins in the central nervous system. She received her PhD in Neurosciences, Molecular and Cell Biology at the Rouen University in 2000. She then spent 2 years on a post-doctoral position in the Pr Colquhoun’s laboratory at University College of London, UK. There, she has developed fast-concentration-jump techniques to mimic electrical fast synaptic inputs on recombinant NMDA receptors and acquired expertise in molecular biology through mutagenesis of NMDA receptor subunits. In 2002, she obtained a permanent position as Chargée de Recherche (CR) at Inserm and became in 2010 leader of the team “Astrocyte and Vascular Niche”. She is now Research Director at Inserm and co-head of the international platform “Cancer and Cognition” under the French North-West Canceropole. She published 90 scientific papers and gave 40 national or international conferences. She develops translational projects on G-protein-coupled receptors (GPCRs) and G proteins in cerebro-glio-vascular pathologies including the development of high-grade gliomas (angiogenesis and invasion), on molecular signalings and cellular mechanisms of chemotactic cell migration, on the impact of cancer and cancer therapies on brain function, on new strategies for prevention of cognitive dysfunctions induced by chemotherapy and on local strategies for glioblastoma treatment and functional rehabilitation in preclinical models.

Dr CHEN Yao, M.D.

Responsible of preclinical and clinical research, Institute of experimental surgery (ICE) Coordination doctor of International Medical Affairs. He is a Staff physician, Surgical Oncologist at Centre Leon Berard, Lyon, France. Graduated from the Faculty of Medicine of Jiao Tong University, Shanghai, China, Dr Yao Chen received specialized training in Digestive surgery, Endocrinal and metabolism diseases, and Oncological surgery in France. He got his equivalence of M.D. in 2009. In parallel, he’s got Master’s degrees in Anatomy and in Cancer Research. He is highly involved in innovations in surgical development as de responsible of the

Sylvain FISSON

Sylvain Fisson is Professor of Immunology at the Evry/Paris-Saclay University. With a solid background in immunology and neuroimmunology, he has developed expertise in ocular and cerebral immune responses in the context of autoimmunity (eg. uveitis, EAE) and tumor immunology (eg. Primary Central Nervous System Lymphomas). He has contributed to the development of innovative diagnostic (multiplex cytokine measurements) and therapeutic (new glycoengineered anti-CD20 mAb ; cultured Ag-specific nTreg cells) tools (3 patents).

Celio Pouponnot

Celio Pouponnot defended his PhD in 1996 (UMPC Sorbonne University) on the role of Maf transcription factors in cancer. He, then, performed his post-doctoral training in Joan Massagué's team (Memorial Sloan Kettering Cancer Center, NYC, USA) where he studied the TGFβ/Smad signaling pathway. He is now Research director (CNRS) at Institut Curie (France). He has strong expertise in signaling pathways in cancer. His group has contributed to the understanding of the role of the Maf transcription factors in oncogenesis by using biochemical and functional approaches both in vitro and in vivo using in mouse models. Projects are now focusing on medulloblastoma, a pediatric tumor of the cerebellum. Celio Pouponnot identified one of the first target genes of the MAF transcription factors (Pouponnot et al. 1995 Mol. Cell. Biol.) and cloned MAFA, a new member of this family (Benkhelifa et al., 1998 Oncogene). He demonstrated that MAF proteins display highly context dependent oncogenic activities and can act both as oncogenes and tumor suppressors (Pouponnot et al. 2006 Oncogene). His team identified the major regulatory phosphorylations that control MAF transcription factors activity. Maf oncogenic activity is highly dependent on these phosphorylations mediated by GSK3 and his team deciphered the molecular mechanisms of this control (Rocques et al., 2007 Mol. Cell). His team brought the proof of concept that these phosphorylations can be therapeutically targeted in Multiple Myeloma (Herath et al., 2014 Blood Cancer J). Importantly, these identified phosphorylations represent a key regulatory process for the MAF transcription factors. Indeed, mutations in human families that specifically prevents this process are associated with developmental abnormities and specific syndromes in human (Niceta et al., 2015 AJHG). He proposed a model of the role of MAF proteins in cancer in which their pro-tumorigenic role is uncoupled to their physiological role (Eychène et al, 2008 Nat. Rev. Cancer). This model has been validated by showing that NRL, a MAF transcription factor specifically expressed in photoreceptor cells of the retina, plays a key role in a group of medulloblastoma. NRL establishes an abnormal identity in these cancers and is required for their growth. This work highlights the role of abnormal cell identity and challenges the concept of "lineage addiction" in cancer (Garancher et al., 2018, Cancer Cell). The team has developed strong activities and expertise on brain tumors, especially medulloblastoma. The ongoing projects focus on deciphering molecular aspects of Medulloblastoma progression, focusing on signaling pathways and transcription factors. Through diverse collaborations, the team is also starting projects on the efficacy of radiotherapy (radiotoxicity and radioresistance) in pediatric brain tumors. Mail : celio.pouponnot@curie.fr https://science.curie.fr/equipe-eychene-pouponnot

Yann Gaston-Mathé

Yann is a seasoned R&D professional, strategy consultant and biotech entrepreneur with 20+ years of experience in pharma (Servier, Ipsen), molecular diagnostics (IntegraGen) and strategy consulting (Capgemini Consulting, BearingPoint, Cepton).He is also a skilled data scientist with several patents and publications in the field of biostatistics and biomarkers discovery and validation. Yann is Co-founder and CEO of Iktos, a leading chemical research Artificial Intelligence company focusing on medicinal chemistry and new drug design. Iktos is developing innovative AI technology based on deep generative models, which enables to design compounds that are optimized in silico to meet all the success criteria of a small molecule drug discovery project.
Yann est diplômé de l’Ecole Polytechnique et de L’institut National d’Agronomie. Il est un entrepreneur aguerri, qui cumule plus de 20 ans d’expérience dans la R&D, l’innovation et le conseil stratégique dans la pharma et les bio technologies. Yann est aussi un data scientist, inventeur de nombreux brevets et rédacteur de plusieurs publications dans le domaine de la découverte et la validation de biomarkers. Yann est cofondateur et Directeur Général d’Iktos, une start-up de pointe française qui utilise l’IA dans la découverte et la retro-synthèse de molécules pharmaceutiques.

Catherine BRENNER

Catherine Brenner is a CNRS Research Director since 2010. She is the director of the CNRS UMR 9018-Metsy (Metabolic and systemic aspects in tumorigenesis for new therapeutic approaches) located in Gustave Roussy Cancer Center (Villejuif, France). She is the scientific head of a high-throughput facility for drug discovery (University of Paris Saclay). As a scientist, she and her colleagues discovered the cooperation of Bax and ANT in cell death and studied the role of the permeability transition pore, a mitochondrial polyprotein complex, as a target for anti-cancer chemotherapy for more than 15 years. Since 2010, her research interests focus on the interplay of mitochondria, metabolism and cell death in pathophysiology for the search for novel strategies for targeted therapies. She is currently developing new tools to investigate the metabolic impact of mitochondrio-nuclear dialog in cancer. She coordinated several international and national research programs with academic as well as biotech partners (ANR PCV, ANR France-Portugal, Labex LERMIT). She published more than 150 articles, reviews and books and hold 6 patents in oncology and cardio-oncology.

Annie Borgne-Sanchez

Annie Borgne-Sanchez (PhD in 1998) is President and CEO/CSO of MITOLOGICS SAS (Medecine University of Créteil, France). Annie has a strong expertise in cell and mitochondrial biology and drug discovery. Annie previously worked on cell cycle and cancer with Dr Laurent Meijer at the CNRS (PhD studies), with the Nobel Prize Prof. Paul Nurse at the Cancer Research UK and with Dr John Hickman at Institut de Recherches Servier. Next, she worked on mitochondrial targeting and mechanisms of cell death at Theraptosis SA, a spin-off of the Pasteur Institute in Paris where she was responsible for the R&D activities in drug-discovery. She is the author of 30 publications in peer-reviewed international journals and co-inventor of 4 patents. She developed screening platforms to identify compounds toxicity or efficacy at the mitochondrial level that are used at MITOLOGICS for internal R&D projects and CRO activity (> 80 clients from Pharmas, Biotechs and Academic labs, worldwide).

Christophe Lautrette

Dr. Zuzana Krupova

Dr. Zuzana Krupova is R&D manager at Excilone and chief of ExcilOmics core facility. She received her Ph.D. in Food technology at the Faculty of Biotechnology and Food resources at the SUA (Slovakia) and completed her postdoctoral training at INRA of Jouy en Josas and ENVA Maison-Alfort, France in the field of human microbiota presenting growth factors implemented in intestinal lengthening and role of exosomes as mediators of intercellular communication. In this context, she was in charge of managing the projects funded by the French National Research Agency (ANR), in collaboration with teams from different European institutions (Pasteur Institute, German Institute of Human Nutrition and ENVA Maison Alfort). Dr. Krupova has extensive experience in molecular and cellular biology and omics tools. She was further involved in projects focused on the optimization of pre-treatment, sorting conditions and characterization of circulating tumoral cells (CTCs), exosomes and cfDNA aiming to determine prognosis, recurrence and treatment in head and neck cancer. Zuzana Krupova has been working for several years now on the new robust methods for extracellular vesicles’ (EV) and exosome isolation, validation of isolated populations and optimization of strategies for the analysis of EV content (nucleic acids, proteins, lipids, metabolites), in line with the objective of Excilone to offer the service of analyzing the exosomes to the scientific community and to develop diagnostic kits.

Peijing Zhang

Pubished more than 20 papers on top-tier journals such as Nature Medicine, Nature Cell Biology, Nature Immunology, Nature Communications and so on. By using molecular, cellular and xenograft models, firstly identified the underlined mechanism how breast cancers acquired radioresistance, and clarified the correlation between Epithelial Mesenchymal Transition (EMT) and breast cancer radioresistance (Nature Cell Biology,2014). Sencondly, by using nanotechnology, efficiently delivered microRNA into mice and significantly inhibited the breast cancer radioresistance (Nature Communications, 2014), which shows the very promising translational potentiality. Moreover, identified a new potential therapeutic target for triple negative breast cancers which are tolerant to EZH2 inhibitors treatment. Blocking this new enzyme activity will significantly decrease the lung metastasis of triple negative breast cancers.

Bertrand Mollereau

B. Mollereau biosketch

• Professor Bertrand Mollereau (ResearcherID: S-4447-2017) is the head of the Apoptosis and Neurogenetics Group at the Laboratory of Biology and Modelling of the Cell (LBMC) at the ENS-Lyon, France.
• Prof. Mollereau obtained his PhD in Immunology in 1997 from the University of Paris. He performed post-doctoral studies in Pr Claude Desplan's laboratory at the Rockefeller University and New York University and was appointed to the position of Assistant Professor at the Rockefeller University in Hermann's Steller laboratory (2001-2006).
• In 2006, Prof. Mollereau was appointed as a full professor at the ENS-Lyon, where he leads a research group investigating the mechanisms of cell death and pathophysiology of neurodegenerative diseases using Drosophila, mouse, and human cellular models. He has 20 years of expertise in the field of cell death mechanisms and 15 years of experience as a group leader using Drosophila as model system to investigate pathological mechanisms.
• Prof. Mollereau has pioneered the concept of ER preconditioning by demonstrating the neuroprotective effects of mild ER stress, and his group first coined the term "ER hormesis" to describe this effect.
• He has also worked quiet extensively on p53 responses (apoptosis, autophagy and necrosis) and their importance during development and in the formation of cancer. Finally, for the last few years, his lab has focused on the importance of lipid metabolism in neurodegeneration and in particular retinal diseases. Selected recent Publications

• 1. Napoletano F, Baron O, Vandenabeele P, Mollereau B, Fanto M. Intersections between Regulated Cell Death and Autophagy. Trends Cell Biol 2019. 10.1016/j.tcb.2018.12.007.
• 2. Robin M, Issa AR, Santos CC, Napoletano F, Petitgas C, Chatelain G, Ruby M, Walter L, Birman S, Domingos PM, Calvi BR, Mollereau B. Drosophila p53 integrates the antagonism between autophagy and apoptosis in response to stress. Autophagy 2018. 10.1080/15548627.2018.1558001.
• 3. Van Den Brink DM, Cubizolle A, Chatelain G, Davoust N, Girard V, Johansen S, Napoletano F, Dourlen P, Guillou L, Angebault-Prouteau C, Bernoud-Hubac N, Guichardant M, Brabet P, Mollereau B. Physiological and pathological roles of FATPmediated lipid droplets in Drosophila and mice retina. PLoS Genet 2018, 14(9): e1007627. 10.1371/journal.pgen.1007627.
• 4. Napoletano F, Gibert B, Yacobi-Sharon K, Vincent S, Favrot C, Mehlen P, Girard V, Teil M, Chatelain G, Walter L, Arama E, Mollereau B. p53-dependent programmed necrosis controls germ cell homeostasis during spermatogenesis. PLoS Genet 2017, 13(9): e1007024. 10.1371/journal.pgen.1007024.
• 5. Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 2014, 15(4): 233-249. 10.1038/nrn3689.

Jean-Michel Lagarde

Jean-Michel is an Engineer in optics and image analysis, graduated of the National School of Physics of Marseille in 1990. He has over 20 years experience as project manager and head of a unit research in Imaging and Engineering of the skin in the Pierre Fabre Laboratories. After a first experience as Founder and President of a first company in 2012 in the field of aid in the early detection of melanoma, he now devotes to the development of Imactiv-3D bringing his skills in imaging, image treatment and corporate management.

Dr. Jiang LIU

Tingshen LI

Ying FU

Christelle Monville obtained a PhD in Neurobiology at the French University of Créteil in 2000. She is currently professor at Evry’s University and team leader at the Istem lab (France). Since ten years, the objectives of her group (Istem, www.istem.eu) are (1) to develop pre-clinical studies required for the development of human pluripotent stem cells cellular therapy for the treatment of a number of monogenic retinal diseases and (2) disease modeling and drug discovery using patient-specific human induced Pluripotent Stem (hiPS). Replacement of defective retinal pigment epithelium (RPE) by new RPE cells derived from human embryonic stem cells (hESC) provides a novel rational approach for treating forms of blindness that affect the RPE. First attempts in clinical trials demonstrated safety for the delivery of such cells as a suspension. Transplanting a functional monolayer of RPE cells is the next challenge to effectively cure patients. We successfully developed, under clinically compatible conditions, a tissue-engineered product (TEP) consisting of RPE cells derived from hESCs disposed on a biocompatible substrate: the human amniotic membrane. The future will be to provide more complex tissue and upscale the production of retinal cells.

CNRS research director (DR2), Head of the laboratory “Chromatin dynamics and metabolism in cancer” at the CNRS UMR9018 METSY (Metabolic and systemic aspects of oncogenesis for new therapeutic approaches), Gustave Roussy

-CNRS research director (DR2), Head of the laboratory of Nuclear Organization and Pathologies at the Institut Gustave Roussy -Director, Joint French-Russian Cancer Research Laboratory (CNRS LIA1066 LFR2O)

Dr. Guillaume Dorothée is a tenured Senior Investigator in neuroimmunology at the French National Institute of Health and Medical Research (INSERM) and team leader at the Saint-Antoine Research Center in Paris, France. He obtained his Ph.D in Immunology from University Pierre and Marie Curie in Paris, and trained as a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in New York, and Curie Institute in Paris. His current main research interests focus on understanding the role of neuroimmune interactions in the pathophysiology of neurodegenerative disorders, and developing innovative immunotherapy approaches and immune-related biomarkers in such conditions. Based on a translational research approach, his laboratory addresses the interplay between peripheral adaptive immunity and innate neuroinflammation in Alzheimer’s disease and related disorders. Guillaume Dorothée is a Scientific Council member of Association France Alzheimer, an Executive Committee member of the French Society for NeuroImmunology (CFNI), and an Steering Committee member of the International Society to Advance Alzheimer's Research and Treatment (ISTAART) – PIA “Immunity and Neurodegeneration”.

Laurent Pépin got à Ph.D in Genetics from University Orsay (Paris-Saclay) . He was a researcher for 3 years at the laboratory of INRA in Jouy-en-Josas and CIRAD of Guadeloupe, then he did a 3-year post-doctoral stay at NIH, Bethesda, USA dedicated to molecular and cellular biology. Laurent then joined a star-up in Clermont Ferrand developing a natural dye. Then, he worked in various commercial and industrial companies first as scientific support for high-throughput sequencing then in different position in sales, marketing and Business Development in molecular and haemostasis diagnostic and for Contract Research Organisations in preclinical and genomics services, always in international positions. Laurent has brought to Genopole his experience and network of more than 20 years at the national and international level with from start up to big pharmaceutical companies. Laurent joined Genopole at the end of October 2013.

Dr. Yama A. Abassi is VP of Global Strategic Business Development and Growth at ACEA Biosciences. He received his undergraduate degree in biochemistry with Honors from State University of New York/Stony Brook in May of 1992 and a PhD degree in Molecular, Cell and Developmental Biology from University of California at Santa Barbara in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research as an NIH Post-Doctoral fellow in 1999 and performed his postdoctoral work on delineating oncogene signaling pathways and its role in cancer biology. Dr. Abassi joined ACEA Biosciences in 2003 to develop a new technology for real-time cell assessment using microelectronics. Dr. Abassi’s efforts in this field has earned him over 30 publications and 10 patents and has led to the successful development and commercialization of the instruments globally. While at ACEA, he has led both scientific and commercial teams for the Global commercialization, distribution and support of ACEA’s proprietary technology. Dr. Abassi continues to pursue research interest in developing technologies and applications for predictive cell-based assays in the immune-oncology and safety/tox fields.